Literature DB >> 2146374

The composition of Photofrin II.

C J Byrne1, L V Marshallsay, A D Ward.   

Abstract

The compositions of Photofrin II and haematoporphyrin derivative (HPD) were examined. Dihaematoporphyrin ester was unambiguously synthesized and shown by high performance liquid chromatography (HPLC) not to be a significant component of Photofrin II. Hydrolysis studies showed the presence of an acid-stable oligomer in Photofrin II which comprised about 40% of of an acid-stable oligomer in Photofrin II which comprised about 40% of the total sample. A dimer derivative was isolated from this oligomeric material by fully dehydrating the methyl-esterified acidic hydrolysis product of Photofrin II. The structure of this dimer, in which two porphyrin units are linked by a three-carbon bridge containing a double bond and a methyl group, was determined by nuclear magnetic resonance (NMR) and fast atom bombardment (FAB) mass spectrometry. An analogous trimer was also isolated and identified. Structures for the hydroxyl-containing precursors to the dimer and trimer, and for the acid-stable oligomeric material in Photofrin II, are suggested. The acid-stable oligomeric material is produced in the sodium hydroxide polymerization step of the preparation of Photofrin II.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146374     DOI: 10.1016/1011-1344(90)85070-d

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  2 in total

1.  Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer. A case report.

Authors:  M Schaffer; A Hofstetter; B Ertl-Wagner; R Batash; J Pöschl; P M Schaffer
Journal:  Strahlenther Onkol       Date:  2013-10-26       Impact factor: 3.621

2.  Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach.

Authors:  C S Loh; A J MacRobert; G Buonaccorsi; N Krasner; S G Bown
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.